A study assessing the pharmacokinetic/Pharmacodynamic (PK/PD) modeling for providing guidance for Avatrombopag (AVA) dose switching to Eltrombopag in Chronic Immune Thrombocytopenia (ITP)
Latest Information Update: 06 Jan 2021
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Pharmacodynamics; Pharmacokinetics
- 06 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology